These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 14613455)

  • 1. Alternate financial incentives in multi-tiered formulary systems to improve accountability for outcomes.
    Chung RS; Taira DA; Noh C
    J Manag Care Pharm; 2003; 9(4):360-5. PubMed ID: 14613455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report.
    Fry RN; Avey SG; Sullivan SD
    Value Health; 2003; 6(5):505-21. PubMed ID: 14627057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMCP Format dossier requests: manufacturer response and formulary implications for one large health plan.
    Spooner JJ; Gandhi PK; Connelly SB
    J Manag Care Pharm; 2007; 13(1):37-43. PubMed ID: 17269835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers.
    Nichol MB; Knight TK; Epstein J; Honda DH; Tretiak R
    J Manag Care Pharm; 2007 May; 13(4):360-71. PubMed ID: 17506602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulary management in the Department of Defense.
    Trice S; Devine J; Mistry H; Moore E; Linton A
    J Manag Care Pharm; 2009 Mar; 15(2):133-46. PubMed ID: 19236127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of a three-tier formulary on antidepressant utilization and expenditures.
    Hodgkin D; Parks Thomas C; Simoni-Wastila L; Ritter GA; Lee S
    J Ment Health Policy Econ; 2008 Jun; 11(2):67-77. PubMed ID: 18509214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacy benefit management companies.
    Taniguchi R
    Am J Health Syst Pharm; 1995 Sep; 52(17):1915-7. PubMed ID: 8528857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the Level of Satisfaction and Unmet Data Needs for Specialty Drug Formulary Decisions in the United States.
    Choi Y; Navarro RP
    J Manag Care Spec Pharm; 2016 Apr; 22(4):368-75. PubMed ID: 27023690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions.
    Grabowski H; Mullins CD
    Soc Sci Med; 1997 Aug; 45(4):535-44. PubMed ID: 9226779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Web-based survey to assess the perceptions of managed care organization representatives on use of copay subsidy coupons for prescription drugs.
    Nemlekar P; Shepherd M; Lawson K; Rush S
    J Manag Care Pharm; 2013 Oct; 19(8):602-8. PubMed ID: 24074006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The arrival of economic evidence in managed care formulary decisions: the unsolicited request process.
    Neumann PJ
    Med Care; 2005 Jul; 43(7 Suppl):27-32. PubMed ID: 16056006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weighing the evidence: trends in managed care formulary decision making.
    de Lissovoy G
    J Clin Psychiatry; 2003; 64 Suppl 17():29-32. PubMed ID: 14680425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Academy of Managed Care Pharmacy's format for formulary submission.
    Penna P
    Manag Care Interface; 2001 Jun; 14(6):61-2. PubMed ID: 11432152
    [No Abstract]   [Full Text] [Related]  

  • 14.
    Curtiss FR; Fry RN; Avey SG
    J Manag Care Spec Pharm; 2020 Jul; 26(7):798-816. PubMed ID: 32584678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does a One-Size-Fits-All Cost-Sharing Approach Incentivize Appropriate Medication Use? A Roundtable on the Fairness and Ethics Associated with Variable Cost Sharing.
    Graff JS; Shih C; Barker T; Dieguez G; Larson C; Sherman H; Dubois RW
    J Manag Care Spec Pharm; 2017 Jun; 23(6):621-627. PubMed ID: 28530519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.
    Shirneshan E; Kyrychenko P; Matlin OS; Avila JP; Brennan TA; Shrank WH
    J Clin Pharm Ther; 2016 Feb; 41(1):64-9. PubMed ID: 26778812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical care: pharmacy's mission for the 1990s.
    Penna RP
    Am J Hosp Pharm; 1990 Mar; 47(3):543-9. PubMed ID: 2316539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The case for a value-based formulary: striving for total lowest net cost.
    Weart W; Bauman GR
    Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience.
    Watkins JB; Minshall ME; Sullivan SD
    J Manag Care Pharm; 2006; 12(9):726-35. PubMed ID: 17249905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.